Develops immuno-oncology therapies using innate cell engagers to treat cancer by harnessing the body's immune system.
Affimed N.V. is a dynamic clinical-stage biopharmaceutical company specializing in the discovery and development of cutting-edge cancer immunotherapies across the United States, Germany, and the rest of Europe. At the forefront of its innovative pipeline is AFM13, the company's lead product candidate. AFM13 has advanced through various clinical stages, including completion of a Phase II study for peripheral T-cell lymphoma, Phase IIa trials for CD30-positive lymphoma, and Phase I trials for Hodgkin lymphoma, showcasing its potential in addressing diverse oncological indications.
In addition to AFM13, Affimed N.V. is actively developing AFM24, a tetravalent bispecific innate cell engager targeting epidermal growth factor receptor (EGFR) and CD16A, currently in Phase IIa trials for advanced cancers. The company's pipeline also includes AFM28, an innate cell engager in preclinical development for acute myeloid leukemia, and AFM32, another innate cell engager in preclinical stages targeting solid tumors. These innovative therapies underscore Affimed's commitment to pioneering novel approaches in cancer treatment.
Founded in 2000 and headquartered in Heidelberg, Germany, Affimed N.V. (formerly known as Affimed Therapeutics B.V.) has established strategic collaborations with prestigious institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., Roivant Sciences Ltd., and Artiva Biotherapeutics Inc. These partnerships, along with a research funding agreement with The Leukemia & Lymphoma Society, bolster Affimed's research capabilities and accelerate the development of its promising immunotherapeutic candidates, aiming to transform the landscape of cancer care globally.